A Zimbryta recall was issued in Europe after the multiple sclerosis drug was associated with severe side effects. 

Last month, the European Medicines agency determined that the risks associated with the drug Zinbryta outweighed its benefits, and they decided to pull the drug from the market in the interest of protecting patients’ health.

Zinbryta is a prescription drug manufactured by Biogen and AbbVie designed to treat multiple sclerosis, an autoimmune disease in which the immune system eats away the lining got the nerves, disrupting communication between the brain and the body. This condition can result in many symptoms including impaired movement and coordination, vision loss, and fatigue. Though symptoms can be lessened, multiple sclerosis is chronic and can be fatal.

Drugs like Zinbryta are designed to lessen the symptoms of multiple sclerosis and help patients live a more comfortable life. But in the case of Zinbryta, the drug can cause more harm than good. Experts say that the drug “poses a risk of serious and potentially fatal immune reactions affecting the brain, liver and other organs.”

Patient reports reveal that these side effects can be experienced at the start of treatment, and even can be experienced months after they stop taking the drug. Research is inconclusive in determining what patients are at highest risk of experiencing these side effects, but a Zimbryta recall was issued in Europe due to these findings.

Zimbryta Recall

In March, Biogen and AbbVie, the makers of the drug, issued a voluntary Zimbryta recall from hospitals and pharmacies in the European Union. The drug was only available for a short time — it was first approved in 2016. In 2017, the drug was restricted for use in patients who had already been treated with other treatment for multiple sclerosis, and did not have other options. These restrictions were in place because research had already shown that the drug had negative effects on the liver.

The drug has also been withdrawn from the market in the United States over similar concerns about the drug’s efficacy and safety. However, many patients were prescribed the drug during its short time on the market before the Zinbryta recall and may be experiencing severe side effects.

Lawyers are investigating patients claims of physical, emotional, and financial injury incurred by taking the drug. If it is discovered that Biogen and AbbVie knew or should have known that the drug was dangerous but marketed it nonetheless, or if it is discovered that they were negligent in determining the drug’s risks, the companies may be liable for consumer injury.

If you or a loved one took the prescription multiple sclerosis drug Zinbryta and experienced severe side effects, you may have a legal claim. If you are not sure that symptoms you are experiencing are a result of your Zinbryta use, an experienced Zinrbyta recall lawyer can help you determine if you have a legal claim. Joining a Zinbryta recall lawsuit could help hold the drug’s manufacturers accountable and could help you receive the compensation you deserve.